Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A)

Annals of Hematology

Volumn 85, Issue 9, 2006, Pages 583-590

  Li, Guzi ^a   Hundemer, Michael ^a   Wolfrum, Sonja ^a   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a   Witzens Harig, Mathias ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antigen; CDKN1A; Multiple myeloma; PAK2; T cell

Indexed keywords

CD8 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PROTEIN P21; PROTEIN SERINE KINASE; TUMOR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD ANALYSIS; BURKITT LYMPHOMA; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; PROLYMPHOCYTE; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EPITOPES, T-LYMPHOCYTE; HEMATOLOGIC NEOPLASMS; HLA-A2 ANTIGEN; HUMANS; MODELS, IMMUNOLOGICAL; P21-ACTIVATED KINASES; PLASMA CELLS; PROTEIN-SERINE-THREONINE KINASES;

EID: 33747862728     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0137-x     Document Type: Article

References (33)

1. Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484-489
2. Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97
3. Barlogie B, Shaughnessy J, Zangari M, Tricot G (2002) High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol 29(6 Suppl 17):26-33 (Review)
4. Bokoch GM (1998) Caspase-mediated activation of PAK2 during apoptosis: proteolytic kinase activation as a general mechanism of apoptotic signal transduction? Cell Death Differ 5(8):637-645
5. Brossart P, Schneider A, Dill P et al (2001) The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC-1 specific cytotoxic T-lymphocytes. Cancer Res 61:6846-6850
6. Brown RD, Yuen E, Nelson M, Gibson J, Joshua D (1997) The prognostic significance of T cells receptor beta gene rearrangements and idiotype-reactive T cell in multiple myeloma. Leukemia 11:1312-1317
7. Choi C, Witzens M, Bucur M, Feuerer M, Sommerfeldt N, Trojan A, Ho A, Schirrmacher V, Goldschmidt H, Beckhove P (2005) Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 105(5):2132-2134
8. Dhodapkar MV, Krasovsky J, Olson K (2002) T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 99:13009-13013
9. Dhodapkar MV, Geller MD, Chang DH et al (2003) A reversible defect in Natural Killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197:1667-1676
10. Dhodapkar MV, Krasovsky J, Osman K, Geller M (2003) Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 11:1753-1757
11. Dudley M, Wunderlich J, Robbins K et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002:850-854
12. Farace F, Orlanducci F, Dietrich PY et al (1994) T cell repertoire in patients with B chronic lymphocytic leukemia. J Immunol 153:4281-4283
13. Feuerer M, Beckhove P, Bai L et al (2001) Therapy of human tumors in NOD/ SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7:452-458
14. Goldschmidt H, Hegenbart U, Wallmeier M, Moos M, Haas R (1997) High-dose chemotherapy in multiple myeloma. Leukemia 11(Suppl 5):S27-S531
15. Gregory W, Richards M, Malpas J (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 10:334-342
16. Hjorth M, Holmberg E, Rodjer S, Turesson I, Westin J, Wisloff F (1999) Survival in conventionally treated younger (<60 years) multiple myeloma patients: No improvement during two decades. Nordic Myeloma Study Group (NMSG). Eur J Haematol 62:271-277
17. Janson CH, Grunewald J, Österborg A, Dersimonian H, Brenner MB, Mellstedt H, Wigzell H (1991) Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood 77:1776-1780
18. Kay N, Leong T, Kyle RA et al (1999) Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma 33:127-133
19. Massaia M, Dianzani U, Bianchi A, Camponi A, Boccasoro M, Pileri A (1988) Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clin Exp Immunol 73:214-218
20. + T cells in patients with multiple myeloma and paraproteinemia. Blood 87:3297-3306
21. Ohtomo T, Sugamata Y, Ozaki Y et al (1999) Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 258:583-591
22. Pellat-Deceunynck C, Mellerin MP, Labarriere N et al (2000) The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 30:803-809
23. Rudel T, Bokoch GM (1997) Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276(5318):1571-1574
24. Rudel T, Zenke FT, Chuang TH, Bokoch GM (1998) p21-activated kinase (PAK) is required for Fas-induced JNK activation in Jurkat cells. J Immunol 160(1):7-11
25. Simons-Evelyn M, Bailey-Dell K, Toretsky JA, Ross DD, Fenton R, Kalvakolanu D, Rapoport AP (2001) PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and otherhighly proliferative malignant cells. Blood Cells Mol Diseases 27(5):825-829
26. Tricot G (2000) Multiple myeloma. In: Hoffmann R (ed) Hematology: principles and practice. Churchill Livingstone, New York, pp 1398-1415
27. Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, Gribben JG (2000) Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 6(6):667-672
28. Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA, Eisen HN (1994) Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med 180:1283-1293
29. van Baren N, Brasseur F, Godelaine D et al (1999) Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94:1156-1164
30. Wen T, Mellstedt H, Jondal M (1990) Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J Exp Med 171:659-666
31. Wen YJ, Barlogie B, Yi Q (2001) Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: Evidence for their capacity to lyse autologous primary tumor cells. Blood 97:1750-1755
32. + subsets. Br J Haematol 96:338-345
33. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M et al (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99(5):1745-1757